Genetic Sucrase-Isomaltase Deficiency (GSID), also known as Congenital Sucrase-Isomaltase Deficiency (CSID), is a disorder that causes a reduction of the enzyme activity needed to break down and absorb table sugar (sucrose) and other sugars from starch.
Genetic Sucrase-Isomaltase Deficiency (GSID) can be diagnosed by abnormal results from a disaccharidase activity test or a brief Sucraid® therapeutic trial. A sucrose intolerance hydrogen breath test or genetic testing may aid in the diagnosis of GSID.
Sucraid® (sacrosidase) Oral Solution is the only FDA-approved enzyme replacement therapy that facilitates breakdown of sucrose (sugar) into simpler forms for absorption from the intestine into the blood. Sucraid® is usually taken with each meal or snack, mixed into 2-4 ounces of water, milk or infant formula.